全文获取类型
收费全文 | 1512483篇 |
免费 | 110943篇 |
国内免费 | 2359篇 |
专业分类
耳鼻咽喉 | 21948篇 |
儿科学 | 52344篇 |
妇产科学 | 43333篇 |
基础医学 | 217569篇 |
口腔科学 | 39862篇 |
临床医学 | 130746篇 |
内科学 | 300791篇 |
皮肤病学 | 32988篇 |
神经病学 | 116885篇 |
特种医学 | 60178篇 |
外国民族医学 | 693篇 |
外科学 | 233000篇 |
综合类 | 33183篇 |
现状与发展 | 2篇 |
一般理论 | 515篇 |
预防医学 | 111918篇 |
眼科学 | 33855篇 |
药学 | 111474篇 |
2篇 | |
中国医学 | 3061篇 |
肿瘤学 | 81438篇 |
出版年
2018年 | 15967篇 |
2017年 | 12029篇 |
2016年 | 13309篇 |
2015年 | 15141篇 |
2014年 | 20765篇 |
2013年 | 31985篇 |
2012年 | 43144篇 |
2011年 | 45559篇 |
2010年 | 27717篇 |
2009年 | 26218篇 |
2008年 | 43516篇 |
2007年 | 46763篇 |
2006年 | 46908篇 |
2005年 | 45554篇 |
2004年 | 44437篇 |
2003年 | 42949篇 |
2002年 | 41885篇 |
2001年 | 73743篇 |
2000年 | 76484篇 |
1999年 | 64856篇 |
1998年 | 17465篇 |
1997年 | 15912篇 |
1996年 | 16183篇 |
1995年 | 15400篇 |
1994年 | 14515篇 |
1993年 | 13481篇 |
1992年 | 50748篇 |
1991年 | 49867篇 |
1990年 | 48439篇 |
1989年 | 46261篇 |
1988年 | 42489篇 |
1987年 | 41628篇 |
1986年 | 38833篇 |
1985年 | 37318篇 |
1984年 | 27850篇 |
1983年 | 23496篇 |
1982年 | 13660篇 |
1981年 | 12331篇 |
1979年 | 24894篇 |
1978年 | 17408篇 |
1977年 | 14724篇 |
1976年 | 13712篇 |
1975年 | 14941篇 |
1974年 | 17437篇 |
1973年 | 16893篇 |
1972年 | 15548篇 |
1971年 | 14184篇 |
1970年 | 13434篇 |
1969年 | 12223篇 |
1968年 | 11242篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
22.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
23.
24.
25.
26.
Marta Rozanski Valentin Neuhaus Emily Thornton Stéphanie J. E. Becker James P. Rathmell David Ring 《Journal of hand and microsurgery》2015,7(1):30-35
This study used the National Survey of Ambulatory Surgery (NSAS) database to measure the incidence of and risk factors for symptoms in the ambulatory surgery center and problems within 24 h after isolated carpal tunnel release (CTR). The NSAS contained records on 400,000 adult patients with carpal tunnel syndrome who were treated with CTR in 2006, based on ICD-9 codes. The type of anesthesia used and factors associated with symptoms and problems were sought in bivariate and multivariable statistical analyses. The mean duration of the procedure was 16 ± 8.8 min. Only 5 % were performed under local anesthesia without sedation, 45 % with IV sedation, 28 % regional anesthesia, and 19 % general anesthesia. Symptoms in the ambulatory surgery center or a problem within 24 h after discharge were recorded in 10 % of patients, all of them minor and transient, including difficulties with pain and its treatment. The strongest risk factors were male sex, age of 45 years and older, and participation of an anesthesiologist. Local anesthesia and regional anesthesia were associated with more perioperative symptoms and postoperative problems. Most CTR are performed with some sedation in the United States. CTR is a safe procedure: one in 10 patients will experience a minor issue in the perioperative or immediate postoperative period. 相似文献
27.
28.
29.
30.